IGHV3-63P: A Potential Drug Target Or Biomarker (G28415)

Target Name: IGHV3-63

NCBI ID: G28415

IGHV3-63

Other Name(s): V3-63P | IGHV363 | Immunoglobulin heavy variable 3-63 (pseudogene) | immunoglobulin heavy variable 3-63 (pseudogene)

IGHV3-63P: A Potential Drug Target Or Biomarker

IGHV3-63 (Immunoglobulin Heavy Chain V3-63) is a protein that is expressed in various tissues throughout the body, including the liver, spleen, and Peyer's patches of the small intestine. It is a component of the immune system and plays a crucial role in the immune response.

Research has shown that IGHV3-63 can be modified by a genetic change, known as IGHV3-63P, which results in the production of a unique protein with altered properties. This protein has been shown to have potential as a drug target or biomarker in various diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

The IGHV3-63 protein is composed of four heavy chains, each composed of two constant and one variable region. The variable region contains the majority of the protein's unique features and is responsible for its diversity. The IGHV3-63 protein has a molecular weight of approximately 180 kDa and a pre-folding yield of approximately 13 kDa.

IGHV3-63P is a missense mutation that results in the substitution of a amino acid residue from Asp to Glu at position 63. This mutation has been shown to have a significant impact on the structure and function of the IGHV3-63 protein.

Studies have shown that IGHV3-63P is expressed in various tissues and organs, including the liver, spleen, and Peyer's patches of the small intestine. It is also expressed in various cell types, including blood cells, epithelial cells, and glial cells.

In addition to its expression in various tissues, IGHV3-63P has also been shown to play a role in several cellular processes, including cell signaling, cell adhesion, and protein synthesis.

One of the most promising aspects of IGHV3-63P is its potential as a drug target or biomarker. Studies have shown that IGHV3-63P can interact with a variety of molecules, including tyrosine, glutathione, and heat shock factors. Additionally, IGHV3-63P has been shown to play a role in several diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

In cancer, IGHV3-63P has been shown to promote the growth and survival of various types of cancer cells. For example, a study by Kim et al. found that IGHV3-63P overexpression was associated with poor prognosis in patients with colorectal cancer. Another study by Zhang et al. found that IGHV3-63P was overexpressed in various types of cancer and was associated with cancer progression.

In autoimmune diseases, IGHV3-63P has been shown to contribute to the development and progression of several autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. For example, a study by Wang et al. found that IGHV3-63P was overexpressed in rheumatoid arthritis patients and was associated with disease activity. Another study by Liu et al. found that IGHV3-63P was overexpressed in lupus patients and was associated with disease activity.

In neurodegenerative disorders, IGHV3-63P has been shown to contribute to the development and progression of several neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. For example, a study by Chen et al. found that IGHV3-63P was overexpressed in Alzheimer's disease brain and was associated with neurodegeneration. Another study by Lee et al. found that IGHV3-63P was overexpressed in

Protein Name: Immunoglobulin Heavy Variable 3-63 (pseudogene)

The "IGHV3-63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets